We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Incisionless Robotic Surgery Benefits Oropharyngeal Cancer Treatment

By HospiMedica International staff writers
Posted on 27 Sep 2016
TransOral Robotic Surgery (TORS), alone or in conjunction with chemotherapy or radiation may offer oropharyngeal cancer patients good outcomes and survival, according to a new study.

Researchers at Henry Ford Hospital (Detroit, MI, USA) conducted a retrospective study that included 53 oropharyngeal cancer patients (83% male, 77% Caucasian, mean age 60.8 years) who underwent TORS for cancer at the base of tongue, tonsils, soft palate, or pharynx. Among them, 37% underwent TORS alone, 11.4% received additional radiation therapy, and 50% received both chemotherapy and radiation therapy. The majority of patients (63%) were able to receive a lower dose of radiation after TORS, which reduces the risk of radiation side effects.

Image: The TORS procedure offers a new option for treating oropharyngeal cancer without visible scarring (Photo courtesy Henry Ford Hospital).
Image: The TORS procedure offers a new option for treating oropharyngeal cancer without visible scarring (Photo courtesy Henry Ford Hospital).

The researchers identified that 81% of the patients were positive to p16, a marker for human papilloma virus (HPV). When three-year survival, cancer control, and metastasis results were reviewed, patients that were negative to the p16 marker had 100% survival and low cancer recurrence when TORS was the first line of treatment, as well as when TORS was followed by chemotherapy and/or radiation therapy. The study was presented at the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) annual meeting, held during September 2016 in San Diego (CA, USA).

“For non-surgical patients, several studies have shown that p16 positive throat cancers, or HPV- related throat cancers, have better survival and less recurrence than p16 negative throat cancers,” said lead author Tamer Ghanem, MD, PhD, director of head and neck oncology and reconstructive surgery at Surgery at Henry Ford Hospital. “Within our study, patients treated with robotic surgery had excellent results and survival, irrespective of their p16 status.”

TORS is a group of minimally invasive robotic surgery techniques that enable surgeons to remove benign and malignant tumors within the parapharyngeal space, a pyramid-shaped area that lies near the base of the skull and connects several deep compartments of the head and neck. It is lined with many large blood vessels, nerves and complex facial muscles, making access to the space via traditional surgical options often impossible or highly invasive. TORS is performed through the patient's mouth, resulting in shorter, virtually scarless head and neck surgery.

Related Links:
Henry Ford Hospital


Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Transducer Covers
Surgi Intraoperative Covers
New
Ultrasonic Cleaner
Cole-Parmer Ultrasonic Cleaner with Digital Timer

Latest Surgical Techniques News

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Novel Sensory System Enables Real-Time Intra-Articular Pressure Monitoring

Endoscopic Surgical System Enables Remote Robot-Assisted Laparoscopic Hysterectomy